Navigation Links
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
Date:3/12/2009

exposed to a very potent stimulant (TRAP-thrombin receptor agonist peptide)," said Enrico Veltri, M.D., group vice president of global clinical research, cardiovascular and metabolic disease, Schering-Plough Research Institute. "These data, along with subsequent data from Phase II acute coronary syndromes (ACS) and stroke studies conducted in Japan, suggest that TRA is a novel medication that targets a pathway to platelet aggregation not addressed by existing medications."

The 1,030-patient TRA-PCI trial was designed to evaluate the safety and tolerability of TRA in patients undergoing PCI. A secondary objective was to assess whether patients treated with the compound in addition to standard-of-care therapies had fewer cardiovascular events such as heart attack, need for urgent coronary revascularization, or death at 60 days compared to patients treated with the standard of care alone. While not powered to establish efficacy, the study did report a non-statistically significant 46 percent reduction in cardiovascular events at the highest TRA dose tested compared to standard of care alone. Preliminary results were presented in March 2007 at the American College of Cardiology/i2 Summit in New Orleans by David J. Moliterno, M.D., Chief of Cardiovascular Medicine, University of Kentucky College of Medicine, and Medical Director of the Linda and Jack Gill Heart Institute, on behalf of the TRA-PCI investigators.

Study Design

The Phase II TRA-PCI trial was a multinational, randomized, double-blind, placebo-controlled dose-ranging trial assessing both oral loading doses as well as maintenance doses of Schering-Plough's TRA. The trial enrolled 1,030 patients 45 years or older, with coronary artery disease for whom PCI was planned, and randomized to one of three oral loading doses of TRA (10mg, 20mg or 40mg) or placebo in a 3:1 ratio of active drug to placebo. The loading doses were increased in a sequential fas
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
2. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
3. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
4. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
5. Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting
6. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
7. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
11. Berlin Hearts EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... from FDA, Favorable Scientific Advice from EMEA and Phase 3 ... Cell ... Dr. Giuseppe Giaccone,Chief of the Medical Oncology Branch at ... double-blind,placebo-controlled Phase 2 trial with talactoferrin alfa in non-small cell,lung ...
... Bionomics Limited (ASX:,BNO) today announced the initiation of treatment ... its anti-cancer drug, BNC105., The BNC105 Phase I ... will be treated with BNC105 on days 1 and ... trial will be conducted at clinical,sites within the Cancer ...
Cached Medicine Technology:Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 2Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 3Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 4Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 5Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 6Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 7Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105 2Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105 3
(Date:4/23/2014)... of the gastro-intestinal tract has long been considered to ... the Sahlgrenska Academy have used refined microscopic techniques that ... surface of the gastro-intestinal tract is only as large ... , The digestive tract, which passes from the mouth ... a length of about 5 meters in a normal ...
(Date:4/23/2014)... Bethesda, MD (April 23, 2014) The American ... announce the 2014 AGA Research Scholars. The AGA ... young investigators to develop independent and productive research ... Research Scholar Awards fund an additional year allowing ... is committed to supporting junior faculty who are ...
(Date:4/23/2014)... 2014 Five for-profit and non-profit organizations in ... in Proof of Concept grants to accelerate maturation ... products, the Life Sciences Discovery Fund (LSDF) announced ... Program grant to the Washington Biotechnology & Biomedical ... to train the next generation of entrepreneurs and ...
(Date:4/23/2014)... journal Oncotarget , explored tumour heterogeneity ... own DNA signatures within the same cancer. Such ... targeted treatment strategies. , Firstly they confirmed the ... the KRAS or BRAF mutation. Secondly, they found ... mutation have that specific mutation present uniformly throughout ...
(Date:4/22/2014)... school sport in the United States with 1 million ... the Center for Injury Research and Policy at Nationwide ... the occurrence and distribution patterns of basketball-related injuries treated ... setting among adolescents and teens. , The study, published ... examined data relating to adolescents 13-19 years of age ...
Breaking Medicine News(10 mins):Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3
... Clements International develops unique suite of insurance solutions for the medical ... and India, Clements has designed liability, accident and trip cancellation insurance ... ... Washington, DC (PRWEB) September 11, 2008 -- Clements International develops ...
... PITTSBURGH, Sept. 10 , Who: ... appreciation to guests for supporting the,chain,s smoke-free policy with a free ... September 11, 5 p.m. to 8 p.m. (with purchase of a ... Eat,n Park -- the state,s leading family dining chain -- is,giving ...
... services, today announced that it was selected to ... support services for independent physicians affiliated with El ... solutions designed for smaller medical practices. ITelagen, which ... is providing professional help desk services and support ...
... Australia, Sept. 10 Ellex Medical Lasers,Limited (ASX: ... global,reach with the establishment of a direct sales ... be formally launched at the European Society of ... September 2008, Ellex,Deutschland GmbH will focus initially on ...
... Pay for ... Medical Bills, 30% of Consumers Receiving Care for a Critical Illness Have Not Recovered ... Financially, ... pay for major medical recovery expenses and both sexes,largely agree that a critical illness would ...
... WEST PALM BEACH, Fla., Sept 10 If ... a bag of chips or a quart of ... with emotional eating, which can,now be helped with ... ), the first vegan, gluten-free vitamin with ...
Cached Medicine News:Health News:Clements International Develops Insurance for Medical Tourism Industry 2Health News:El Camino Hospital Selects ITelagen for Multimillion-Dollar Electronic Medical Records (EMR) Initiative; Program Will Offer More Than 100 Participating Physicians State-of-the-Art Service and Support 2Health News:El Camino Hospital Selects ITelagen for Multimillion-Dollar Electronic Medical Records (EMR) Initiative; Program Will Offer More Than 100 Participating Physicians State-of-the-Art Service and Support 3Health News:Ellex Commences Direct Sales in Germany 2Health News:Guardian Survey: Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 2Health News:Guardian Survey: Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 3Health News:Guardian Survey: Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 4Health News:Guardian Survey: Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 5Health News:Guardian Survey: Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 6Health News:Stress-Related and Emotional Eating Can Be Curbed With the Vitamin Code(TM) Perfect Weight Formula 2Health News:Stress-Related and Emotional Eating Can Be Curbed With the Vitamin Code(TM) Perfect Weight Formula 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: